FT Options’s Larimar Therapeutics LRMR Stock Holding History

FT Options’s Portfolio LRMR Stock Details LRMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-3,542	Closed	-$3K	–	324
2016 Q3	$3K	Sell	3,542 -291	-8%	-$13.2K	﹤0.01%	340
2016 Q2	$53K	Sell	3,833 -4,650	-55%	-$368K	0.05%	201
2016 Q1	$34K	Buy	8,483 +983	+13%	+$77.6K	0.04%	190
2015 Q4	$76K	Buy	+7,500	New	+$1.2M	0.06%	143

Other funds holding LRMR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

FT Options's LRMR Position: Q3 2017 in Review

FT Options reduced its Larimar Therapeutics (LRMR) stake by 58% in Q3 2017, selling an estimated $123K and leaving 2,138 shares worth $90K. The position accounts for 0.14% of the portfolio, ranked #105.

FT Options first reported a position in LRMR in Q4 2015 and has held it in 8 quarters since. The position peaked at $568K in Q1 2017. 62 funds tracked by Wall St. Rank hold LRMR as of Q3 2017.

FT Options held 2,138 shares of Larimar Therapeutics worth $90K as of Q3 2017.
FT Options sold 2,951 Larimar Therapeutics shares in Q3 2017, an estimated $123K.
Larimar Therapeutics made up 0.14% of FT Options's portfolio in Q3 2017, its #105 holding.
FT Options first reported a position in Larimar Therapeutics in Q4 2015 and has held it in 8 quarters since.
FT Options's Larimar Therapeutics position peaked at $568K in Q1 2017.
62 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q3 2017.

Based on FT Options's 13F filing for Q3 2017, filed 13 Nov 2017.